Form 8-K Vanda Pharmaceuticals For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Vanda Pharmaceuticals (VNDA) PT Raised to $13 at Cantor Fitzgerald
August 1, 2024 6:35 AM EDTCantor Fitzgerald analyst Charles Duncan raised the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $13.00 (from $11.00) while maintaining a Overweight rating.
The analyst comments "Overall, we see VNDA as a differentiated Neuro-Innovator with a broadening neuropsych portfolio that should garner investors' interest as... More
